Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.18
+0.37 (3.42%)
Jul 30, 2025, 12:14 PM - Market open
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Zevra Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $23.25, which forecasts a 107.96% increase in the stock price over the next year. The lowest target is $18 and the highest is $29.
Price Target: $23.25 (+107.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +159.39% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +132.56% | Jul 2, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +123.61% | May 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $23 → $25 | Strong Buy | Maintains | $23 → $25 | +123.61% | Mar 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +96.78% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
95.16M
from 23.61M
Increased by 303.00%
Revenue Next Year
169.65M
from 95.16M
Increased by 78.29%
EPS This Year
0.96
from -2.28
EPS Next Year
0.67
from 0.96
Decreased by -30.19%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 104.4M | 243.6M | 357.0M | ||
| Avg | 95.2M | 169.7M | 248.6M | ||
| Low | 85.3M | 112.3M | 173.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 342.0% | 156.0% | 110.4% | ||
| Avg | 303.0% | 78.3% | 46.5% | ||
| Low | 261.1% | 18.0% | 2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.54 | 2.03 | 3.48 | ||
| Avg | 0.96 | 0.67 | 1.77 | ||
| Low | -0.33 | 0.05 | 0.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 112.1% | 421.2% | ||
| Avg | - | -30.2% | 165.3% | ||
| Low | - | -94.9% | 8.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.